| Literature DB >> 31370817 |
Hui Guo1, Seyed M Hosseini-Moghaddam2, William Hodge3,4.
Abstract
BACKGROUND: The aim of this study was to compare the postoperative corneal biomechanical properties between small incision lenticule extraction (SMILE) and other corneal refractive surgeries.Entities:
Keywords: Corneal biomechanical properties; Meta-analysis; Small incision lenticule extraction; Systematic review
Mesh:
Year: 2019 PMID: 31370817 PMCID: PMC6676534 DOI: 10.1186/s12886-019-1165-3
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Flow Diagram of Literature Search And Study Selection
Example of how to combine effect size and variance of change score of CH and CRF within studies
| Study | Outcome (mmHg) | SMILE | LASIK | Effect size (Hedges’ g) | Variance of Hedges’ g | Combined effect size | Correlation between CH and CRF | Combined variance | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | N (eye) at last follow-up | Mean | SD | N (eye) at last follow-up | |||||||
| Alper Agca [ | CH | −1.94 | 1.52 | 30 | −1.98 | 1.5 | 30 | 0.03 | 0.06 | −0.07 | 0.71 | 0.06 |
| CRF | −2.96 | 1.69 | 30 | −2.69 | 1.44 | 30 | −0.17 | 0.07 | ||||
| Di Wu [ | CH | −1.94 | 0.82 | 37 | −2.34 | 1.08 | 34 | 0.42 | 0.06 | 0.48 | 0.71 | 0.05 |
| CRF | −3.59 | 0.91 | 37 | −4.29 | 1.6 | 34 | 0.54 | 0.06 | ||||
| Wenjing Wu [ | CH | −1.86 | 1.13 | 75 | −2.23 | 1.33 | 75 | 0.3 | 0.03 | 0.4 | 0.71 | 0.02 |
| CRF | −3.14 | 1.06 | 75 | − 3.8 | 1.53 | 75 | 0.5 | 0.03 | ||||
| Bingjie Wang [ | CH | −2.55 | 1.44 | 50 | − 2.53 | 1.38 | 56 | −0.01 | 0.04 | 0.4 | 0.71 | 0.03 |
| CRF | −2.24 | 1.29 | 50 | −3.33 | 1.34 | 56 | 0.82 | 0.04 | ||||
Abbreviation: CH corneal hysteresis, CRF corneal resistance factor, LASIK laser-assisted in situ keratomileusis, SD standard deviation, SMILE small incision lenticule extraction
Baseline characters of studies
| First author | Publication year | Study location | Study design | Follow-up (months) | Group | N (eye) at baseline | Age (year) Mean ± SD | SE (D) Mean ± SD | CCT ( | IOP (mmHg) Mean ± SD |
|---|---|---|---|---|---|---|---|---|---|---|
| Anders H. Vestergaard [ | 2014/2019 | Denmark | RCT | 6 | SMILE | 34 | 35.00 ± 7.00 | −7.65 ± 1.11 | 552.00 ± 30.00 | 16.10 ± 3.00 |
| FLEX | 34 | 35.00 ± 7.00 | −7.59 ± 0.97 | 553.00 ± 28.00 | 15.80 ± 2.80 | |||||
| Danyang Wang [ | 2014 | China | Prospective cohort | 3 | SMILE (SE ≤ −6.00D) | 124 | 24.85 ± 4.34 | −4.45 ± 1.00 | 553.57 ± 25.50 | 15.75 ± 3.12 |
| FS-LASIK (SE ≤-6.00D) | 49 | 25.47 ± 3.71 | −4.24 ± 1.40 | 547.49 ± 35.00 | 14.79 ± 2.87 | |||||
SMILE (SE > −6.00D) | 63 | 24.70 ± 4.68 | −7.38 ± 0.95 | 556.00 ± 26.91 | 16.97 ± 2.78 | |||||
FS-LASIK (SE > −6.00D) | 30 | 23.73 ± 3.94 | −7.60 ± 1.04 | 539.43 ± 34.23 | 16.17 ± 3.23 | |||||
| Iben Bach Pedersen [ | 2014 | Denmark | Cross-sectional | 16 | SMILE | 29 | 40.90 ± 6.73 | −7.10 ± 1.56 | N/A | N/A |
| 28 | FLEX | 31 | 40.50 ± 9.47 | −7.43 ± 1.11 | N/A | N/A | ||||
| 37 | FS-LASIK | 35 | 38.40 ± 44.55 | −7.40 ± 1.18 | N/A | N/A | ||||
| Kazutaka Kamiya [ | 2014 | Japan | RCT | 3 | SMILE | 24 | 31.80 ± 6.00 | −4.10 ± 1.70 | 543.10 ± 32.40 | 13.30 ± 3.20 |
| FLEX | 24 | 31.80 ± 6.00 | −4.10 ± 1.70 | 545.50 ± 31.80 | 13.80 ± 3.30 | |||||
| Di Wu [ | 2014 | China | Prospective cohort | 6 | SMILE | 40 | 25.75 ± 5.40 | −5.71 ± 1.19 | 554.15 ± 24.77 | N/A |
| FS-LASIK | 40 | 24.25 ± 6.02 | −5.80 ± 1.14 | 556.70 ± 30.60 | N/A | |||||
| Alper Agca [ | 2014 | Turkey | RCT | 6 | SMILE | 30 | 26.63 ± 4.57 | −3.62 ± 1.79 | 539.00 ± 28.00 | N/A |
| FS-LASIK | 30 | 26.63 ± 4.57 | −3.71 ± 1.83 | 542.00 ± 37.00 | N/A | |||||
| Yang Shen [ | 2014 | China | Cross-sectional | 3 | SMILE | 17 | 27.06 ± 6.77 | −6.48 ± 1.22 | 557.65 ± 22.56 | N/A |
| LASEK | 18 | 22.89 ± 6.42 | −6.09 ± 1.87 | 533.06 ± 29.38 | N/A | |||||
| FS-LASIK | 17 | 29.53 ± 7.42 | −8.71 ± 2.02 | 562.71 ± 20.96 | N/A | |||||
| Rui Dou [ | 2015 | China | Retrospective cohort | 3 | SMILE | 36 | 24.00 ± 8.07 | −3.87 ± 0.95 | 538.00 ± 20.60 | 15.64 ± 2.04 |
| LASEK | 35 | 23.00 ± 3.36 | −3.51 ± 1.21 | 532.00 ± 32.40 | 15.99 ± 3.50 | |||||
| Shervin Mir Mohi Sefat [ | 2015 | Germany | Prospective cohort | 3 | SMILE | 43 | 36.60 ± 7.70 | −3.81 ± 0.95 | 553.10 ± 29.00 | 15.80 ± 2.60 |
| FS-LASIK | 26 | 36.20 ± 6.70 | −3.65 ± 1.12 | 561.40 ± 30.10 | 15.90 ± 1.90 | |||||
| Wenjing Wu [ | 2015 | China | Retrospective cohort | 3 | SMILE | 75 | 24.25 ± 5.38 | −5.49 ± 1.35 | 547.69 ± 27.06 | 15.80 ± 2.55 |
| FS-LASIK | 75 | 24.28 ± 5.24 | −5.56 ± 1.76 | 545.97 ± 27.71 | 15.79 ± 2.78 | |||||
| Hua Li [ | 2016 | China | Retrospective cohort | 6 | SMILE | 97 | 25.00 ± 6.00 | −5.60 ± 1.43 | 546.75 ± 26.06 | 15.84 ± 2.12 |
| FS-LASIK | 96 | 24.00 ± 6.00 | −5.95 ± 1.78 | 542.86 ± 30.54 | 15.58 ± 2.56 | |||||
| Ihab Mohamed Osman [ | 2016 | Egypt | Retrospective cohort | 1 | SMILE | 25 | 26.28 ± 3.41 | −5.43 ± 1.17 | 532.84 ± 16.37 | 14.89 ± 3.15 |
| LASIK | 25 | 26.88 ± 3.99 | −5.16 ± 1.42 | 527.96 ± 16.21 | 15.59 ± 3.23 | |||||
| Bingjie Wang [ | 2016 | China | Retrospective cohort | 12 | SMILE | 50 | 25.26 ± 6.64 | −7.60 ± 1.12 | 542.96 ± 23.34 | 14.68 ± 2.65 |
| FS-LASIK | 56 | 24.75 ± 6.24 | −7.68 ± 1.19 | 548.00 ± 23.97 | 14.94 ± 2.36 | |||||
| Lei Xia [ | 2016 | China | Prospective cohort | 6 | SMILE | 69 | 25.15 ± 4.42 | −5.04 ± 2.32 | 545.50 ± 28.20 | N/A |
| FS-LASIK | 59 | 23.65 ± 3.87 | −5.13 ± 1.36 | 538.80 ± 31.50 | N/A | |||||
| Minjie Chen [ | 2016 | China | Prospective cohort | 3 | SMILE | 75 | 26.30 ± 4.20 | −4.40 ± 1.00 | 553.00 ± 26.50 | N/A |
| LASEK | 76 | 26.70 ± 5.20 | −3.70 ± 1.10 | 542.40 ± 34.30 | N/A | |||||
| Yusuf Yildirim [ | 2016 | Turkey | Retrospective cohort | 6 | SMILE | 42 | 29.00 ± 5.90 | −3.50 ± 1.00 | 528.10 ± 23.60 | N/A |
| PRK | 42 | 27.60 ± 5.20 | −3.60 ± 0.60 | 517.60 ± 24.60 | N/A | |||||
| Jun Zhang [ | 2016 | China | Prospective cohort | 3 | SMILE | 80 | N/A | −5.12 ± 1.62 | 550.80 ± 25.77 | N/A |
| FS-LASIK | 80 | N/A | −4.87 ± 1.80 | 547.06 ± 29.53 | N/A | |||||
| Rohit Shetty [ | 2017 | India | RCT | 6 | SMILE | 31 | 24.00 ± 1.00 | −6.18 ± 0.41 | 514.18 ± 4.50 | 13.00 ± 0.45 |
| FS-LASIK | 31 | 24.00 ± 1.00 | −7.22 ± 1.32 | 517.00 ± 4.89 | 13.50 ± 0.46 | |||||
| Mohamed Nagy Elmohamady [ | 2018 | Egypt | Prospective cohort | 36 | SMILE | 35 | 24.42 ± 5.91 | −8.05 ± 2.06 | 579.32 ± 10.65 | N/A |
| LASIK | 30 | 23.84 ± 4.75 | −7.49 ± 2.05 | 582.84 ± 12.25 | N/A | |||||
| FS-LASIK | 38 | 23.84 ± 4.75 | −7.14 ± 1.97 | 587.96 ± 12.06 | N/A | |||||
| Manrong Yu [ | 2018 | China | Prospective cohort | 36 | SMILE | 32 | 23.40 ± 4.60 | −4.10 ± 0.80 | 551.10 ± 23.10 | 17.40 ± 4.60 |
| LASEK | 32 | 25.70 ± 5.70 | −3.70 ± 1.00 | 538.30 ± 34.60 | 16.60 ± 2.50 | |||||
| Esraa El-Mayah [ | 2018 | Spain | Prospective cohort | 3 | SMILE | 30 | 29.53 ± 5.37 | −4.17 ± 1.86 | N/A | N/A |
| FS-LASIK | 30 | 27.40 ± 4.95 | −3.97 ± 2.02 | N/A | N/A | |||||
Abbreviations: CCT central corneal thickness, CH corneal hysteresis, CRF corneal resistance factor, FLEX femtosecond lenticule extraction, FS femtosecond Laser, IOP intraocular pressure, LASEK laser-assisted subepithelial keratectomy, LASIK laser-Assisted in situ keratomileusis, N/A not available, PRK photorefractive keratectomy, RCT randomized controlled trial, SD standard deviation, SE spherical equivalent, SMILE small incision lenticule extraction
Data from ocular response analyzer (ORA) measurement
| First author | Procedure | N (eye) at last follow-up | Preoperative CH (mmHg) | Postoperative CH (mmHg) | CH change (mmHg) | Preoperative CRF (mmHg) | Postoperative CRF (mmHg) | CRF change (mmHg) |
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
| Anders H. Vestergaard [ | SMILE | 34 | 11.00 ± 1.70 | 7.80 ± 1.30 | −3.30 ± 1.20 | 10.90 ± 1.90 | 6.40 ± 1.40 | −4.60 ± 1.20 |
| FLEX | 34 | 10.80 ± 1.70 | 8.00 ± 1.10 | −2.70 ± 1.30 | 10.90 ± 1.80 | 6.40 ± 1.40 | −4.50 ± 1.20 | |
| Danyang Wang [ | SMILE(SE ≤ -6.00D) | 124 | 10.56 ± 1.89 | N/A | N/A | 10.48 ± 1.89 | N/A | N/A |
| FS-LASIK (SE ≤ -6.00D) | 49 | 10.45 ± 1.33 | N/A | N/A | 10.07 ± 1.40 | N/A | N/A | |
| SMILE (SE > −6.00D) | 63 | 10.49 ± 1.51 | N/A | N/A | 10.86 ± 1.59 | N/A | N/A | |
| FS-LASIK (SE > −6.00D) | 30 | 10.15 ± 1.48 | N/A | N/A | 10.15 ± 1.70 | N/A | N/A | |
| Iben Bach Pedersen [ | SMILE | 29 | N/A | 8.56 ± 1.02 | N/A | N/A | 7.12 ± 1.24 | N/A |
| FLEX | 31 | N/A | 8.48 ± 1.00 | N/A | N/A | 7.00 ± 1.22 | N/A | |
| FS-LASIK | 35 | N/A | 8.58 ± 0.89 | N/A | N/A | 7.12 ± 1.06 | N/A | |
| Kazutaka Kamiya [ | SMILE | 24 | 10.50 ± 1.30 | 8.50 ± 1.00 | N/A | 10.00 ± 1.70 | 7.10 ± 1.30 | N/A |
| FLEX | 24 | 10.40 ± 1.60 | 8.30 ± 1.10 | N/A | 9.80 ± 1.70 | 6.70 ± 1.40 | N/A | |
| Di Wu [ | SMILE | 37b | N/A | 8.59 ± 1.00 | −1.94 ± 0.82 | N/A | 7.78 ± 1.03 | −3.59 ± 0.91 |
| FS-LASIK | 34b | N/A | 8.11 ± 0.66 | −2.34 ± 1.08 | N/A | 6.94 ± 0.66 | −4.29 ± 1.60 | |
| Alper Agca [ | SMILE | 30 | 10.89 ± 1.79 | 8.95 ± 1.47 | −1.94 ± 1.52 | 10.73 ± 1.71 | 7.77 ± 1.37 | −2.96 ± 1.69 |
| FS-LASIK | 30 | 11.00 ± 1.53 | 9.02 ± 1.27 | −1.98 ± 1.50 | 10.76 ± 1.45 | 8.07 ± 1.26 | −2.69 ± 1.44 | |
| Rui Dou [ | SMILE | 36 | 10.00 ± 0.82 | 8.51 ± 0.84 | −1.48 ± 0.80 | 10.10 ± 0.68 | 7.61 ± 0.83 | −2.49 ± 0.71 |
| LASEK | 35 | 9.99 ± 1.31 | 8.47 ± 1.29 | −1.52 ± 1.23 | 10.21 ± 1.72 | 7.53 ± 1.42 | −2.68 ± 1.03 | |
| Wenjing Wu [ | SMILE | 75 | 10.16 ± 1.30 | 8.30 ± 1.04 | −1.86 ± 1.13 | 10.39 ± 1.52 | 7.25 ± 1.31 | −3.14 ± 1.06 |
| FS-LASIK | 75 | 10.09 ± 1.38 | 7.86 ± 1.03 | −2.23 ± 1.33 | 10.57 ± 1.64 | 6.77 ± 1.13 | −3.80 ± 1.53 | |
| Hua Li [ | SMILE | 44b | 10.16 ± N/A | 7.94 ± 1.07a | N/A | 10.41 ± N/A | 6.83 ± 1.18a | N/A |
| FS-LASIK | 38b | 10.32 ± N/A | 7.84 ± 0.88a | N/A | 10.74 ± N/A | 6.58 ± 1.01a | N/A | |
| Ihab Mohamed Osman [ | SMILE | 25 | 12.03 ± 1.76 | 9.99 ± 1.76 | N/A | 11.42 ± 1.68 | 9.43 ± 1.55 | N/A |
| LASIK | 25 | 11.59 ± 1.86 | 8.46 ± 1.76 | N/A | 11.00 ± 1.89 | 7.45 ± 2.39 | N/A | |
| Bingjie Wang [ | SMILE | 50 | 10.52 ± 1.71 | 7.97 ± 2.05 | −2.55 ± 1.44 | 10.07 ± 1.49 | 7.83 ± 1.64 | −2.24 ± 1.29 |
| FS-LASIK | 56 | 10.85 ± 1.19 | 8.31 ± 1.62 | −2.53 ± 1.38 | 10.62 ± 1.81 | 7.29 ± 1.76 | −3.33 ± 1.34 | |
| Lei Xia [ | SMILE | 69 | 10.99 ± 1.65 | 8.58 ± 1.40 | N/A | 11.26 ± 1.94 | 7.05 ± 1.65 | N/A |
| FS-LASIK | 59 | 10.76 ± 1.67 | 7.97 ± 1.14 | N/A | 10.60 ± 1.99 | 6.31 ± 1.41 | N/A | |
| Minjie Chen [ | SMILE | 67b | 10.40 ± 1.70 | 8.30 ± 1.20 | −2.20 ± 1.40 | 11.00 ± 1.70 | 7.00 ± 1.20 | −4.10 ± 1.40 |
| LASEK | 66b | 10.00 ± 1.20 | 7.70 ± 1.20 | −2.20 ± 1.20 | 10.30 ± 1.40 | 7.00 ± 1.50 | −3.30 ± 1.00 | |
| Yusuf Yildirim [ | SMILE | 42 | 10.90 ± 1.70 | 8.40 ± 1.50 | −2.50 ± 1.10 | 11.10 ± 1.50 | 7.90 ± 1.60 | −3.30 ± 1.10 |
| PRK | 42 | 10.40 ± 1.30 | 8.50 ± 1.30 | −1.90 ± 1.20 | 10.80 ± 1.10 | 7.40 ± 1.50 | −2.70 ± 1.10 | |
| Jun Zhang [ | SMILE | 80 | 10.64 ± 1.09 | 7.91 ± 0.92 | N/A | 10.54 ± 1.53 | 7.07 ± 1.27 | N/A |
| FS-LASIK | 80 | 10.83 ± 1.60 | 8.00 ± 1.32 | N/A | 10.71 ± 1.74 | 6.82 ± 1.40 | N/A | |
| Mohamed Nagy Elmohamady [ | SMILE | 35 | 10.58 ± 0.39 | 8.51 ± 0.51 | N/A | 10.21 ± 0.09 | 8.38 ± 0.59 | N/A |
| LASIK | 30 | 10.62 ± 0.53 | 7.58 ± 0.71 | N/A | 10.19 ± 0.12 | 7.17 ± 0.68 | N/A | |
| FS-LASIK | 38 | 10.71 ± 0.47 | 7.60 ± 0.61 | N/A | 10.22 ± 0.10 | 7.25 ± 0.69 | N/A | |
| Manrong Yu [ | SMILE | 32 | 10.50 ± 2.10 | 8.70 ± 1.40 | N/A | 11.10 ± 1.70 | 7.40 ± 1.10 | N/A |
| LASEK | 32 | 10.10 ± 1.30 | 8.80 ± 1.50 | N/A | 10.20 ± 1.60 | 7.20 ± 1.70 | N/A | |
| Esraa El-Mayah [ | SMILE | 30 | 8.85 ± 1.80 | 7.37 ± 1.29 | −1.44 ± 1.65 | 8.53 ± 2.26 | 6.03 ± 1.63 | −2.49 ± 1.74 |
| FS-LASIK | 30 | 9.83 ± 1.43 | 7.83 ± 1.15 | −1.91 ± 0.77 | 9.76 ± 2.17 | 7.40 ± 1.35 | −2.33 ± 1.27 |
Abbreviations: CH corneal hysteresis, CRF corneal resistance factor, FLEX femtosecond lenticule extraction, FS femtosecond Laser, LASEK laser-assisted subepithelial keratectomy, LASIK laser-Assisted in situ keratomileusis, N/A not available, PRK photorefractive keratectomy, SMILE small incision lenticule extraction. a the value of SD was imputed from the other four studies in the same subgroup. b The number of patients at the last follow-up visit differed from the number at baseline
Postoperative outcomes of Corvis ST (CST)
| First author | Iben Bach Pedersen [ | Yang Shen [ | Sherivin Mir Mohi Sefat [ | Ihab Mohamed Osman [ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SMILE | FLEX | FS-LASIK | SMILE | LASEK | FS-LASIK | SMILE | FS-LASIK | SMILE | LASIK | |
| N (eye) at last follow-up | 29 | 31 | 35 | 17 | 18 | 17 | 43 | 26 | 25 | 25 |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| A1 time (ms) | 6.75 ± 0.16 | 6.76 ± 0.17 | 6.82 ± 0.12 | 7.27 ± 0.20 | 7.35 ± 0.23 | 7.17 ± 0.17 | 6.79 ± 0.24 | 6.83 ± 0.18 | 8.23 ± 0.37 | 7.89 ± 0.44 |
| A1 deflection length (mm) | 1.91 ± 0.27 | 1.83 ± 0.28 | 1.90 ± 0.24 | N/A | N/A | N/A | 1.97 ± 0.24 | 2.06 ± 0.21 | N/A | N/A |
| A2 time (ms) | 21.80 ± 0.38 | 21.70 ± 0.39 | 21.70 ± 0.35 | 23.08 ± 0.44 | 22.80 ± 0.44 | 22.92 ± 0.82 | 21.88 ± 1.11 | 22.05 ± 0.27 | 22.03 ± 1.11 | 20.28 ± 1.87 |
| HC deflection amplitude (mm) | N/A | N/A | N/A | N/A | N/A | N/A | 0.89 ± 0.07 | 0.92 ± 0.08 | N/A | N/A |
| HC deflection length (mm) | 5.93 ± 0.22 | 5.91 ± 0.22 | 5.88 ± 0.18 | N/A | N/A | N/A | 5.76 ± 0.22 | 5.82 ± 0.26 | N/A | N/A |
| HC deformation amplitude (mm) | 1.20 ± 0.05 | 1.18 ± 0.06 | 1.15 ± 0.12 | 1.17 ± 0.11 | 1.08 ± 0.11 | 1.19 ± 0.13 | 1.11 ± 0.09 | 1.12 ± 0.10 | 1.10 ± 0.08 | 1.26 ± 0.07 |
| HC time (ms) | 16.40 ± 0.05 | 16.30 ± 0.56 | 16.10 ± 0.47 | 17.38 ± 0.81 | 17.57 ± 0.72 | 17.57 ± 0.83 | 16.80 ± 0.36 | 16.77 ± 0.37 | 16.32 ± 1.10 | 14.40 ± 1.27 |
| HC Radius (mm) | 6.25 ± 0.59 | 6.11 ± 0.61 | 6.06 ± 0.53 | 5.74 ± 0.91 | 6.30 ± 1.83 | 6.30 ± 1.41 | 6.60 ± 0.70 | 6.60 ± 0.67 | 6.91 ± 1.25 | 7.00 ± 1.06 |
Abbreviations: A application, FS femtosecond laser, HC highest concavity, LASEK laser-assisted subepithelial keratectomy, LASIK laser-assisted in situ keratomileusis, N/A not available, SD standard deviation, SMILE small incision lenticule extraction. Specifically, we chose the subgroup data created in the study of Seafat et al. as this subgroup had a balance of spherical equivalent at baseline between the two intervention groups. Only one study provided the preoperative data of CST measurement. Therefore, we presented only the postoperative outcomes in this table
Fig. 2Forest Plot of Corneal Hysteresis/Corneal Resistance Factor (CH/CRF) for Studies Comparing Small Incision Lenticule Extraction (SMILE) with Femtosecond Laser-assisted in Situ Keratomileusis (FS-LASIK)
Fig. 3Forest Plot of Corneal Hysteresis/Corneal Resistance Factor (CH/CRF) for Studies Comparing Small Incision Lenticule Extraction (SMILE) with Laser-assisted in Situ Keratomileusis (LASIK)
Fig. 4Forest Plot of Corneal Hysteresis/Corneal Resistance Factor (CH/CRF) for Studies Comparing Small Incision Lenticule Extraction (SMILE) with Femtosecond Lenticule Extraction (FLEX)
Fig. 5Forest Plot of Corneal Hysteresis/Corneal Resistance Factor (CH/CRF) for Studies Comparing Small Incision Lenticule Extraction (SMILE) with Laser-assisted Subepithelial Keratectomy (LASEK) /Photorefractive Keratectomy (PRK) Group
Fig. 6Forest Plot of Postoperative Corvis ST System (CST) Outcome for Studies Comparing Small Incision Lenticule Extraction (SMILE) with Femtosecond Laser-assisted in Situ Keratomileusis (FS-LASIK)/Laser-assisted in Situ Keratomileusis (LASIK) Group
Quality checklist
| No. of question | Question | Answer | Score | Anders H. Vestergaard [ | Danyang Wang [ | Iben Bach Pedersen [ | Kazutaka Kamiya [ | Di Wu [ | Alper Agca [ | Yang Shen [ | Rui Dou [ | Shrvin Mir Mohi Sefat [ | Wenjing Wu [ | Hua Li [ | Ihab Mohamed Osman [ | Bingjie Wang [ | Lei Xia [ | Minjie Chen [ | Yusuf Yidirim [ | Jun Zhang [ | Rohit Shetty [ | Mohamed Nagy Elmohamady [ | Manrong Yu [ | EsraaEl-Mayah [ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Is the hypothesis /aim/objective of the study clearly described? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| NO | 0 | |||||||||||||||||||||||
| 2 | Are the main outcomes to be measured clearly described in the Introduction or Methods section? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| NO | 0 | |||||||||||||||||||||||
| 3 | Are the characteristics of the patients included in the study clearly described? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| NO | 0 | X | ||||||||||||||||||||||
| 4 | Are the interventions of interest clearly described? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| NO | 0 | |||||||||||||||||||||||
| 5 | Are the distributions of principal confounders in each group of subjects to be compared clearly described? | YES | 2 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| PARTIALLY | 1 | X | X | X | X | |||||||||||||||||||
| NO | 0 | |||||||||||||||||||||||
| 6 | Are the main findings of the study clearly described? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| NO | 0 | X | ||||||||||||||||||||||
| 7 | Does the study provide estimates of the random variability in the data for the main outcomes? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| NO | 0 | X | ||||||||||||||||||||||
| 8 | Have all important adverse events that may be a consequence of the intervention been reported? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| NO | 0 | X | X | X | X | X | X | X | X | |||||||||||||||
| 9 | Have the characteristics of patients lost to follow-up been described? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||
| NO | 0 | X | X | X | X | X | X | |||||||||||||||||
| 10 | Have actual probability values been reported for the main outcomes except where the probability value is less than 0.001? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||
| NO | 0 | X | X | X | ||||||||||||||||||||
| 11 | Were the subjects asked to participate in the study representative of the entire population from which they were recruited? | YES | 1 | X | X | X | X | X | X | |||||||||||||||
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| 12 | Were those subjects who were prepared to participate representative of the entire population from which they were recruited? | YES | 1 | X | ||||||||||||||||||||
| NO | 0 | X | X | X | ||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||
| 13 | Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||||||
| NO | 0 | X | ||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | |||||||||||||||||
| 14 | Was an attempt made to blind study subjects to the intervention they have received? | YES | 1 | |||||||||||||||||||||
| NO | 0 | X | X | X | X | X | X | X | ||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||||||||
| 15 | Was an attempt made to blind those measuring the main outcomes of the intervention? | YES | 1 | |||||||||||||||||||||
| NO | 0 | X | X | X | X | |||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||
| 16 | If any of the results of the study were based on “data dredging”, was this made clear? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | ||||||||||
| NO | 0 | X | X | X | X | X | X | X | X | X | ||||||||||||||
| UNABLE TO DETERMINE | 0 | X | ||||||||||||||||||||||
| 17 | In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | |||||||||||||||||
| 18 | Were the statistical tests used to asses the main outcomes appropriate? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||
| NO | 0 | X | X | X | X | |||||||||||||||||||
| UNABLE TO DETERMINE | 0 | |||||||||||||||||||||||
| 19 | Was compliance with the inerventions reliable? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | |||||||||||||||||||||||
| 20 | Were the main outcome measures used accurate (valid and reliable)? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | |||||||||||||||||||||||
| 21 | Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | |||||||||||||||||||||
| 22 | Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||
| NO | 0 | |||||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | |||||||||||||||||||||
| 23 | Were study subjects randomised to intervention groups? | YES | 1 | X | X | X | ||||||||||||||||||
| NO | 0 | X | X | X | X | X | X | X | ||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | X | X | ||||||||||||
| 24 | Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable? | YES | 1 | X | ||||||||||||||||||||
| NO | 0 | X | X | X | X | X | X | X | X | X | X | X | ||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | X | X | X | ||||||||||||||
| 25 | Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? | YES | 1 | X | X | X | X | X | X | X | X | X | X | |||||||||||
| NO | 0 | X | X | X | X | X | X | X | X | X | X | |||||||||||||
| UNABLE TO DETERMINE | 0 | X | ||||||||||||||||||||||
| 26 | Were losses of patients to follow-up taken into account? | YES | 1 | X | X | X | X | X | X | X | X | X | X | X | X | |||||||||
| NO | 0 | X | X | X | ||||||||||||||||||||
| UNABLE TO DETERMINE | 0 | X | X | X | X | X | X | |||||||||||||||||
| 27 | Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5% | YES | 1 | X | X | X | X | X | ||||||||||||||||
| NO | 0 | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Total scores | 28 | 20 | 17 | 22 | 17 | 18 | 22 | 19 | 18 | 15 | 20 | 15 | 20 | 19 | 17 | 15 | 16 | 18 | 23 | 16 | 21 | 17 | ||
| excellent (26–28); good (20–25); fair (15–19); poor (≤14) | Good | Fair | Good | Fair | Fair | Good | Fair | Fair | Fair | Good | Fair | Good | Fair | Fair | Fair | Fair | Fair | Good | Fair | Good | Fair |